Deals Of The Week: Gilead/J&J, Hisamitsu/Noven, GSK/Abbott ...
Executive Summary
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
You may also be interested in...
The J&J/ Vanderbilt Tie-Up: Accessing Innovation On The Cheap
With most Big Pharmas facing a steep and costly patent chasm and in-house R&D failing to produce the necessary bridge to patent-challenged franchises, companies have been forced to look for new sources of innovation beyond traditional in-licensing and acquisition. As a result, some drugmakers are looking with renewed interest at the innovation housed in universities. The tie-up between Johnson & Johnson and Vanderbilt University is just the latest example of this important trend.
Shionogi Gains U.S. Sales Force With $1.4 Billion Sciele Acquisition
Shionogi offers strong pipeline, Sciele brings 770-strong sales force to Japan-U.S. pairing.
Takeda's Global Ambition
Takeda Pharmaceutical's drug business started out manufacturing and selling bismuth-the basic ingredient in Pepto-Bismol--in 1895. A century later, it's still chained to the stomach-settling game with Prevacid, a $1.4 billion drug whose patent will expire in 2009, taking with it a huge percentage of Takeda's earnings. That's one big reason why Japan's largest and most international pharmaceutical company is on a US-focused dealmaking tear. Since February, Takeda has inked three major licensing partnerships and completed the largest acquisition in its history in a desperate attempt to shore up a thin pipeline.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: